BridgeBio Pharma (NASDAQ:BBIO) PT Lowered to $43.00 : vimarsana.com

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) had its target price reduced by research analysts at HC Wainwright from $47.00 to $43.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 46.86% from the […]

Related Keywords

Bio Pharma , Raymond James , Bridgebio Pharma , Randalw Scott , Citigroup , Bridgebio Pharma Inc , Investment Advisors Inc , Healthcare Of Ontario Pension Plan Trust Fund , Entrypoint Capital , Cantor Fitzgerald , Assetmark Inc , Get Free Report , Bio Pharma Trading Down , Director Randal , Point Capital , Ontario Pension Plan Trust Fund , Bridgebio Pharma Daily ,